News Focus
News Focus
Post# of 257262
Next 10
Followers 24
Posts 2252
Boards Moderated 0
Alias Born 04/14/2007

Re: DewDiligence post# 132217

Thursday, 12/01/2011 9:51:16 PM

Thursday, December 01, 2011 9:51:16 PM

Post# of 257262
<<Even if NVS/MNTA have some kind of document about the AG...>>

The document they have is a Sanofi press release available at http://sanofi.mediaroom.com/index.php?s=64&item=56

How did I come across this? It is an exhibit to a filing by Amphastar, see my next post


Press Statements

Winthrop U.S., a Sanofi U.S. Company, Announces Discontinuation of Enoxaparin Sodium Injections

November 30, 2011 -- Winthrop U.S., a business of sanofi-aventis U.S. LLC, announces discontinuation of distribution of the Winthrop Enoxaparin Sodium Injection, the authorized generic of Lovenox (Enoxaparin Injection).

This action is in response to an ongoing assessment of market conditions and is limited to this product only. All other products sold under the Winthrop label will continue to be sold in the normal course of business.

Sanofi U.S. continues to provide branded Lovenox which is the most widely studied and most prescribed LMWH in the world with more than 17 years of clinical and real-life experience and with over 2.3 billion prescriptions written in more than 100 countries.
Lovenox is a complex injectable biological product, and its efficacy and safety profile relies heavily on the strict adherence to the specific processes applied in its manufacturing as well as its traceability from the animal mucosa to the finished product.

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up